[Skip to Content]
[Skip to Content Landing]
Research Letter
April 2016

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

Author Affiliations
  • 1Massachusetts General Hospital Cancer Center, Boston
  • 2Harvard Medical School, Boston, Massachusetts
  • 3Department of Radiology, Massachusetts General Hospital, Boston
JAMA Oncol. 2016;2(4):541-543. doi:10.1001/jamaoncol.2015.5009

Third-generation EGFR tyrosine kinase inhibitors (TKIs) that block activating EGFR mutations and the T790M resistance mutation yield marked responses among patients with EGFR mutation–positive lung cancer and acquired resistance to initial TKIs.1,2 Osimertinib (formerly AZD9291) was recently approved by the US Food and Drug Administration, and rociletinib (formerly CO-1686) is under regulatory consideration. Little is known about using third-generation EGFR inhibitors sequentially.

First Page Preview View Large
First page PDF preview
First page PDF preview
×